David Tick, MD
Internal Medicine · Thiensville, WINPI 1972571313
Payments from drug & device makers
Across 226 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$731
- AbbVie$576
- AstraZeneca$321
- Lilly USA, LLC$269
- Novartis$175
- Boehringer Ingelheim$115
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,667100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 47 | $731 |
| AbbVie(2 entities) | 31 | $576 |
| AstraZeneca(2 entities) | 22 | $321 |
| Lilly USA, LLC | 18 | $269 |
| Novartis | 11 | $175 |
| Boehringer Ingelheim | 6 | $115 |
| Gilead | 6 | $112 |
| Novo Nordisk | 6 | $104 |
| Amarin Pharma, Inc. | 5 | $104 |
| Ironwood Pharmaceuticals, Inc | 6 | $103 |
| Nestle Healthcare Nutrition Inc. | 6 | $101 |
| Vanda Pharmaceuticals Inc. | 4 | $94 |
| Phathom Pharmaceuticals, Inc. | 6 | $74 |
| Bayer | 4 | $65 |
| Amgen | 4 | $65 |
| Pfizer | 4 | $58 |
| Mylan Specialty L.p. | 4 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Alkermes, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $40 |
| Agile Therapeutics, Inc. | 3 | $38 |
| Ultragenyx Pharmaceutical Inc. | 3 | $37 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Sanofi | 2 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Sobi, Inc | 2 | $27 |
| Genentech USA, Inc. | 1 | $26 |
| Merck | 2 | $25 |
| Dexcom, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| GSK | 1 | $16 |
| UCB, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Apria Healthcare LLC | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
How this compares
$3,685 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 29 | $30,560 |
| EliquisApixaban | 26 | $21,256 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $13,179 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,142 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $6,816 |
| Rosuvastatin Calcium | 293 | $3,473 |
| Losartan Potassium | 302 | $2,955 |
| FenofibrateFenofibrate Nanocrystallized | 93 | $2,862 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,770 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $2,677 |
| Metoprolol Succinate | 152 | $2,566 |
| Omeprazole | 124 | $2,237 |
| Colesevelam Hcl | 20 | $2,191 |
| Ezetimibe | 117 | $1,999 |
| Atorvastatin Calcium | 149 | $1,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $269 | $30,56029 claims |
| PfizerEliquis | $58 | $21,25626 claims |
| Boehringer IngelheimCombivent Respimat | $115 | $13,17920 claims |
| GSKTrelegy Ellipta | $16 | $12,14214 claims |
| AstraZenecaSymbicort | $321 | $6,81614 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $31 | $1,07583 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Thiensville
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
- Aliaksandr TrusauGreen Bay$1.5M
- Samuel IdarragaWauwatosa$743K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.